Please login to the form below

Not currently logged in
Email:
Password:

Durbin appoints US business development principal

Todd Galles now takes up the role on a permanent basis

Durbin Todd GallesSpecialist medical supplier Durbin has appointed Todd Galles as its business development principal in the US in a permanent capacity.

Galles first joined the UK-headquartered firm in 2014, serving as its US representative in a part-time role, and will now be responsible for growing its clinical trial supply and managed access business there.

He brings over 30 years of sales, marketing and business development experience in the pharma and biotech industries, and has held a number of executive management roles during this time.

Prior to joining Durbin, Galles served as director of business development at C3 Research Associates, business development US liaison for Japanese contract research organisation CMIC, and business development director at US firm BDC.

He also brings experience from dermatology CRO bioskin, medical device and biotech CRO Boston Biomedical Associates, and clinical and data management firm ProPharma Group.

Robert Donnell, head of business development at Durbin, said: “Todd has supported business development outreach in the US part-time for Durbin for more than two years, so now we're delighted to have him on-board full-time.

“Todd brings a huge amount of experience and enthusiasm to the role, and I look forward to continuing to work with him to develop and grow our US business.”

26th September 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....
Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...

Infographics